AD/PD™ 2023 Interactive Program
NEUROEPO IN NEURODEGENERATIVE DISORDERS
Aims
To present the main results of NeuroEPO treatment in patients with neurodegenerative disorders
Methods
NeuroEPO was evaluated in different clinical trials [Spinocerebellar Ataxia type 2 (SCA2), Parkinson disease (PD) and Alzheimer´s disease (AD)]. The SCA2 trial enrolled 34 patients, a half received NeuroEPO and the other half received placebo. Primary endpoint was the change from baseline to month 6 in the spinocerebellar ataxia functional index (SCAFI). The PD trial enrolled 102 patients, allocated to NeuroEPO 0.5 mg or to 1.0 mg or placebo, in three groups of 34 patients each. Primary endpoint was the change from baseline to week 36 in the Unified Parkinson Disease Rating Scale (UPDRS). The AD trial enrolled 174 patients, allocated to NeuroEPO 0.5 mg or to 1.0 mg or placebo, in three groups of 58 patients each. Primary endpoint was the change from baseline to week 48 in the 11-item AD Assessment Scale-Cognitive subscale (ADAS-Cog11).
Results
In SCA2, the 6-month changes in SCAFI score were slightly higher in the NeuroEPO treated-patients than placebo. However, saccade latency was significantly decreased in the NeuroEPO group but not in placebo. In PD, NeuroEPO treated-patients improved their cognitive functions. In AD trial, NeuroEPO treatment reduced ADAS-Cog11 in 4.0 and 5.0 units respectively for the groups of 0.5 and 1.0 mg dose, while placebo increased ADAS-Cog11 in 4.0. No serious adverse events related with NeuroEPO were reported.
Conclusions
NeuroEPO improved clinical outcomes with a good safety profile in patients with SCA2, PD and mild-to-moderate Alzheimer’s clinical syndrome.
Ref:
No comments:
Post a Comment